{"filing":{"accession_number":"0001683168-26-004387","cik":"0001402328","ticker":"SBFMW","company_name":"Sunshine Biopharma Inc.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"sunshine_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1402328/000168316826004387/sunshine_8k.htm"},"events":[{"id":8257,"run_id":7246,"accession_number":"0001683168-26-004387","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"This Item 5.07 discloses shareholder approval by written consent on May 28, 2026, by majority holder Dr. Steve N. Slilaty (86% voting power) authorizing issuance of over 20% of outstanding shares at a discount to Nasdaq minimum price and adjustments to Series C Warrants. The disclosure of shareholder voting results—even by written consent rather than meeting vote—is the core event, and the authorization of dilutive equity issuance at a discount is material to investors.","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2892,"accession_number":"0001683168-26-004387","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This Item 5.07 discloses shareholder approval by written consent on May 28, 2026, by majority holder Dr. Steve N. Slilaty (86% voting power) authorizing issuance of over 20% of outstanding shares at a discount to Nasdaq minimum price and adjustments to Series C Warrants. The disclosure of shareholder voting results—even by written consent rather than meeting vote—is the core event, and the authorization of dilutive equity issuance at a discount is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:40:08.384464+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2892,"accession_number":"0001683168-26-004387","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This Item 5.07 discloses shareholder approval by written consent on May 28, 2026, by majority holder Dr. Steve N. Slilaty (86% voting power) authorizing issuance of over 20% of outstanding shares at a discount to Nasdaq minimum price and adjustments to Series C Warrants. The disclosure of shareholder voting results—even by written consent rather than meeting vote—is the core event, and the authorization of dilutive equity issuance at a discount is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:40:08.384464+00:00","company_name":"Sunshine Biopharma Inc.","ticker":"SBFMW","filing_date":"2026-05-29"}]}